BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 25611175)

  • 1. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
    Lim S; Han J; Kim GM; Han KH; Choi HJ
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1024-31. PubMed ID: 25611175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
    Yang Y; Wen F; Li J; Zhang P; Yan W; Hao P; Xia F; Bi F; Li Q
    Liver Int; 2015 Sep; 35(9):2147-54. PubMed ID: 25676812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels.
    Huang G; Lai EC; Lau WY; Zhou WP; Shen F; Pan ZY; Fu SY; Wu MC
    Ann Surg; 2013 Mar; 257(3):490-505. PubMed ID: 22868358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
    Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma.
    Huang L; Li J; Lau WY; Yan J; Zhou F; Liu C; Zhang X; Shen J; Wu M; Yan Y
    J Gastroenterol Hepatol; 2012 Jan; 27(1):158-64. PubMed ID: 21871026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
    Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
    JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
    Estfan B; Byrne M; Kim R
    Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
    Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
    J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study.
    Yang T; Lu JH; Zhai J; Lin C; Yang GS; Zhao RH; Shen F; Wu MC
    Eur J Surg Oncol; 2012 Aug; 38(8):683-91. PubMed ID: 22621971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
    Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
    Di Costanzo GG; de Stefano G; Tortora R; Farella N; Addario L; Lampasi F; Lanza AG; Cordone G; Imparato M; Caporaso N
    Future Oncol; 2015; 11(6):943-51. PubMed ID: 25760975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
    Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
    Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
    J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.